Natera, the genetic-testing company, announced Nov. 5, 2026, that Solomon Moshkevich was named chief executive and a board member, putting a longtime internal executive in charge as Steve Chapman moves into consulting and board-advisory roles.
An immediate management handoff
The company announcement says the appointment takes effect immediately. Natera said Chapman will remain a consultant for an extended period and continue advising the board. It did not specify the length of that arrangement.
Natera identified co-founder Matthew Rabinowitz as executive chairman. Moshkevich becomes CEO and a board member.
An operating role expanded in 2023
Moshkevich joined Natera in 2011. Its Sept. 18, 2023, leadership announcement promoted him to president of clinical diagnostics, responsible for general managers across the company’s three core testing businesses.
That earlier assignment also included customer service, program management, clinical-trial operations, and regulatory and quality affairs. Those responsibilities describe his previous operating remit; they are not additional appointments announced with the CEO transition.
The 2023 release says he had served as general manager of oncology since 2019. Before joining Natera, he worked in consulting at Bain & Co. and on Parthenon Capital’s private-equity investment team.
Revenue growth, with a quarterly loss
Natera’s separate third-quarter results, also released Nov. 5, show the scale of the business Moshkevich takes over. Revenue for the three months ended Sept. 30 was $794 million, up 34.1% from $592.2 million a year earlier.
The company reported a GAAP net loss of $59.9 million, compared with $87.5 million in the prior-year quarter. Research and development plus selling, general and administrative expenses totaled $576.1 million, versus $482 million a year earlier.
Natera said it processed about 1.09 million tests, compared with 893,600 a year earlier. Its disclosure separates processed tests from tests reported to customers for which revenue was recognized.
Natera raised its full-year revenue forecast to $3.005 billion to $3.035 billion, versus $2.850 billion to $2.910 billion. That is a company projection, not revenue already earned or a result attributable to the incoming CEO.